Monoclonal antibodyFDA-approvedFirst-line
Trastuzumab
How it works
Binds the HER2 receptor on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Breast Cancer— HER2-positive
Efficacy
In clinical trials, around 50% of HER2-positive patients achieved an objective response, with median progression-free survival of approximately 11 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Cardiac Risks in Breast Cancer Patients on Combination Therapy | Breast Cancer | observational | — | Source → |
| Testing a Combination Therapy for ER-Positive, HER-2 Positive Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Comparing Infection Risks of Two Breast Cancer Treatments | Breast Cancer | observational | — | Source → |
| Testing Sotorasib and Trastuzumab Deruxtecan for Lung Cancer with KRAS G12C Mutation | Lung Cancer | phase-1 | — | Source → |
| Trial Tests Combo Cancer Treatment | Breast Cancer | phase-1 | — | Source → |
| Researchers Identify New Ways Cancer Cells Resist Treatment | Breast Cancer | lab-study | — | Source → |
| Trastuzumab Deruxtecan Resistance Varies in HER2-Amplified vs. HER2-Low Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ebastine May Help Overcome Resistance to Trastuzumab in HER2-Positive Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Dual HER2 Blockade Improves Outcomes in HER2-Positive Breast Cancer | Breast Cancer | meta-analysis | The P + H arm showed significant improvements in 3-year EFS rate (RR 1.08, 95% CI 1.00-1.16, p = 0.04), 5-year EFS rate (RR 1.10, 95% CI 1.01-1.20, p = 0.03), and 5-year DFS rate (RR 1.09, 95% CI 0.99-1.20). | Source → |
| Trastuzumab Deruxtecan Shows Promise in Lung Cancer Treatment | Lung Cancer | observational | The median progression-free survival was 7.85 months, and the objective response rate was 51.4%. | Source → |
| New Cancer Treatment Shows Promise in Breast and Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Trastuzumab Emtansine Efficacy and Safety in HER2-Positive Breast Cancer | Breast Cancer | observational | The 4-years disease-free survival (DFS) rate was 92.5% (95%CI=[87;98]). | Source → |
| Comparing Heart Risks of Cancer Treatments for ERBB2-Positive Breast Cancer | Breast Cancer | meta-analysis | The pooled analysis demonstrated a 0.94% incidence of LVEF decrease with trastuzumab emtansine, a 4.20% incidence with trastuzumab deruxtecan, a 4.85% incidence with trastuzumab plus chemotherapy, and a 5.52% incidence with trastuzumab plus pertuzumab plus chemotherapy. | Source → |
| Metabolites Linked to Trastuzumab Resistance in Breast Cancer | Breast Cancer | lab-study | — | Source → |
| European Study on Lung Disease Risk with Breast Cancer Treatment | Breast Cancer | observational | — | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Reducing Trastuzumab Deruxtecan Dose May Not Harm Metastatic Breast Cancer Patients | Breast Cancer | observational | The overall median real-world progression-free survival was 8.1 months. | Source → |
| Trastuzumab Deruxtecan Shows Promise in Treating Advanced Lung Cancer | Lung Cancer | meta-analysis | T-DXd showed a 100% probability of being the best treatment for progression-free survival, ≥59% for overall survival, and ≥80% for overall response rate. | Source → |
| New Imaging Agent Shows Promise for Cancer Detection | Melanoma | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.